National Amphetamine-Type Stimulant Strategy Background Paper

More documents

Recommendations

Info

172 Ressler, K.J., & Nemeroff, C.B. (1999). Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biological Psychiatry, 46 (9), 1219-1233. Riley, S.C.E., James, C., Gregory, D., Dingle, H., & Cadger, M. (2001). Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction, 96 (7), 1035-1047. Ritter, A. (2005). A review of approaches to studying illicit drug markets. Drug policy modelling project. Monograph 08. Melbourne: Turning Point Alcohol and Drug Centre. Roche, A.M. (2007). AOD use by Australian workers: A risky mix. Of Substance, 5 (2). Rogers, R.D., Everitt, B.J., Baldacchino, A., Blackshaw, A.J., Swainson, R., Wynne, K., Baker, N.B., Hunter, J., Carthy, T., Booker, E., London, M., Deakin, J.F., Sahakian, B.J. & Robbins, T.W. (1999). Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms. Neuropsychopharmacology, 20 (4), 322-339. Roiser, J.P., & Sahakian, B.J. (2004). Relationship between ecstasy use and depression: A study controlling for poly-drug use. Psychopharmacology, 173 (3-4), 411-417. Roll, J.M. (2007). Contingency management: An evidence-based component of methamphetamine use disorder treatments. Addiction, 102 (Suppl 1), 114-120. Roll, J.M., Petry, N.M., Stitzer, M.L., Brecht, M.L., Peirce, J.M., McCann, M.J., & Blaine, J. (2006). Contingency management for the treatment of methamphetamine use disorders. American Journal of Psychiatry, 163 (11), 1993-1999. Ross, J. (2007). Illicit Drug Use in Australia: Epidemiology, Use Patterns and Associated Harm (2 nd edition). Sydney: National Drug & Alcohol Research Centre, University of New South Wales. Roth, L. (2006). Law and order legislation in the Australian States and Territories: 2003–2006. Briefing Paper 12/2006. NSW: Parliamentary Library Research Service. Rothman, R.B. & Baumann, M.H. (2003). Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology, 479, 23-40. Salo, R., Nordahl, T.E., Possin, K., Leamon, M., Gibson, D.R., Galloway, G.P., Flynn, N.M., Henik, A., Pfefferbaum, A. & Sullivan, E.V. (2002). Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Research, 111, 65-74. Sansom, D. (2001). Education and Training, National Hepatitis C Resource Manual. Melbourne: Department of Health and Aged Care and Australian Institute of Primary Care, La Trobe University. Schifano, F. (2003). A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology, 173 (3-4), 242-248.
173 Schifano, F., Oyefeso, A., Corkery, J., Cobain, R., Jambert-Gray, R., Martinotti, G., & Ghodes, A.H. (2003). Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Human Psychopharmacology, 18 (7), 519-524. Schloenhardt, A. (2007). The market for amphetamine-type stimulants and their precursors in Oceania. Research in Public Policy Series no 81 Canberra: Australian Institute of Criminology. Sekine, Y., Ouchi, Y., Takei, N., Yoshikawa, E., Nakamura, K., Futatsubashi, M., Okada, H., Minabe, Y., Suzuki, K., Iwata, Y., Tsuchiya, K.J., Tsukada, H., Iyo, M. & Mori, N. (2006). Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Archives of General Psychiatry, 63, 90-100. Semple, S.J., Patterson, T.L., & Grant, I. (2004). The context of sexual risk behaviour among heterosexual methamphetamine users. Addictive Behaviors, 29, 807-810. Seymour, J. (1988). Dealing With Young Offenders. Law Book Company, North Ryde, 1988. Shearer, J. (2007). Psychosocial approaches to psychostimulant dependence: A systematic review. Journal of Substance Abuse Treatment, 32, 41-52. Shearer, J., & Gowing, L.R. (2004). Pharmacotherapies for problematic psychostimulant use: A review of current research. Drug and Alcohol Review, 23, 203-211. Shearer, J., Sherman, J., Wodak, A., & van Beek, I. (2002). Substitution therapy for amphetamine users. Drug and Alcohol Review, 21, 179-185. Shearer, J., Wodak, A., Mattick, R.P., et al. (2001). Pilot randomised controlled study of dexamphetamine for amphetamine dependence. Addiction, 96, 1289-1296. Sheridan, J., Bennett, S., Coggan, C., Wheeler, A., & McMillan, K. (2006). Injury associated with methamphetamine use: A review of the literature. Harm Reduction Journal, 3. Shewan, D., Dalgarno, P., & Reith, G. (2000). Perceived risk and risk reduction among ecstasy users: The role of drug, set, and setting. International Journal of Drug Policy, 10, 431-453. Shoptaw, S., Huber, A., Peck, J., Yang, X., Liu, J., Dang, J., Roll, J., Shapiro, B., Rotheram- Fuller, E. & Ling, W. (2006). Randomised, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 85, 12-18. Shoptaw, S., & Reback, C.J. (2007). Methamphetamine use and infectious disease related behaviors in men who have sex with men: Implications for interventions. Addiction, Vol. 102 (Suppl 1), 130-135. Shoptaw, S., Reback., C.J., Peck, J.A., Yang, X., Rotheram-Fuller, E., Larkins, S. Veniegas, R.C., Freese, T.E. & Hucks-Ortiz, C. (2005). Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug and Alcohol Dependence, 78, 125-134.
Page 1:
National Amphetamine-Type Stimulant
Page 4 and 5:
ii Acknowledgments This research wo
Page 6 and 7:
iv Table of contents Acknowledgemen
Page 8 and 9:
vi List of tables Table 1.1: Amphet
Page 10 and 11:
viii
Page 12 and 13:
2 The NDS framework and the Law Enf
Page 14 and 15:
4 Table 1.1: Amphetamine-type stimu
Page 16 and 17:
6 particularly on the Pacific Coast
Page 18 and 19:
8 Figure 1.1: MDMA (ecstasy) tablet
Page 20 and 21:
10 a 10-year period. While some of
Page 22 and 23:
12 Figure 1.4: Forms of methampheta
Page 24 and 25:
14 Figure 1.5: Median purity of met
Page 26 and 27:
16 As noted, the route of administr
Page 28 and 29:
18 Chapter 2: Setting the Context T
Page 30 and 31:
20 Figure 2.2: Prevalence of ecstas
Page 32 and 33:
22 19 years (Dunn et al., 2007). Th
Page 34 and 35:
24 The use of MDMA among police det
Page 36 and 37:
26 this survey is conducted with th
Page 38 and 39:
28 models might be useful. On the o
Page 40 and 41:
30 the questionnaire in February 20
Page 42 and 43:
32 2.5 Summary According to the lat
Page 44 and 45:
34 anxiety, agitation, tremor, teet
Page 46 and 47:
36 may be stronger than the link wi
Page 48 and 49:
38 Srisurapanot and colleagues (200
Page 50 and 51:
40 Psychiatric problems appear to o
Page 52 and 53:
42 In 2005, there was a total of 68
Page 54 and 55:
44 The most recent EDRS survey foun
Page 56 and 57:
46 same reasons they use the drugs
Page 58 and 59:
48 Shoptaw and Reback (2007) review
Page 60 and 61:
50 It has also been speculated that
Page 62 and 63:
52 Parental ATS use In addition to
Page 64 and 65:
54 The Minnesota Department of Heal
Page 66 and 67:
56 Chapter 4: Prevention and Harm R
Page 68 and 69:
58 should cover the full range of d
Page 70 and 71:
60 specific drug (Spoth et al., 200
Page 72 and 73:
62 be applied regularly and systema
Page 74 and 75:
64 Strategies targeting vulnerable
Page 76 and 77:
66 Examples of particular periods t
Page 78 and 79:
68 At-risk workplaces There is incr
Page 80 and 81:
70 The consultation forum with Abor
Page 82 and 83:
72 young people was noted in the su
Page 84 and 85:
74 and/or others); mental health ef
Page 86 and 87:
76 of the fact that frequently peop
Page 88 and 89:
78 Sexual risk behaviour is a furth
Page 90 and 91:
80 • Cleaning up; • Transport o
Page 92 and 93:
82 Assessing the risks of illicitly
Page 94 and 95:
84 4.4 Challenges of applying preve
Page 96 and 97:
86 but a number of studies are now
Page 98 and 99:
88 The pack included a video, train
Page 100 and 101:
90 Chapter 5: Treatment and Service
Page 102 and 103:
92 to the occurrence of amphetamine
Page 104 and 105:
94 In relation to the need for spec
Page 106 and 107:
96 These studies replicate earlier
Page 108 and 109:
98 addressed not only the drug user
Page 110 and 111:
100 Research conducted in the subse
Page 112 and 113:
102 users, data that may be general
Page 114 and 115:
104 that limit brain exposure to me
Page 116 and 117:
106 only significant difference was
Page 118 and 119:
108 through the use of antipsychoti
Page 120 and 121:
110 to develop the capacity of the
Page 122 and 123:
112 It was also suggested that link
Page 124 and 125:
114 as new evidence emerges. New ps
Page 126 and 127:
116 border in 2000 (McKetin et al.,
Page 128 and 129:
118 Table 6.1: Number of clandestin
Page 130 and 131:
120 Table 6.2: Examples of domestic
Page 132 and 133: 122 Tasmania In 2004, strengthened
Page 134 and 135: 124 Recommendations from the consul
Page 136 and 137: 126 Although there are a number of
Page 138 and 139: 128 illegal drugs. When incarcerate
Page 140 and 141: 130 heroin) (Payne et al., 2007). I
Page 142 and 143: 132 Some examples of diversion prog
Page 144 and 145: 134 Other research has compared psy
Page 146 and 147: 136 Rehabilitation in Corrections T
Page 148 and 149: 138 Synthetic Drugs measure will im
Page 150 and 151: 140 • Stealing from motor vehicle
Page 152 and 153: 142 criminal offences There continu
Page 154 and 155: 144 • Increase international coll
Page 156 and 157: 146 • Ensuring offence and penalt
Page 158 and 159: 148 Law enforcement agencies are pl
Page 160 and 161: 150 Appendix 1 National consultatio
Page 162 and 163: 152 Appendix 2 Written submissions
Page 164 and 165: 154 Australian Institute of Health
Page 166 and 167: 156 Bowers, J. & Johnson, S. (2003)
Page 168 and 169: 158 Crits-Christoph, P., Siqueland,
Page 170 and 171: 160 Drug & Alcohol Services South A
Page 172 and 173: 162 Halkitis, P.N., Parsons, J.T.,
Page 174 and 175: 164 Hull, P., Rawstorne, P., Zablot
Page 176 and 177: 166 Leek, L., Seneque, D., & Ward,
Page 178 and 179: 168 McKetin, R., McLaren, J., Kelly
Page 180 and 181: 170 NSW Health (2006). Psychostimul
Page 184 and 185: 174 Small, W., Kerr, T., Charette,
Page 186 and 187: 176 United Nations Office for Drug
Page 188 and 189: 178
Page 190: 180
show all

National Amphetamine-Type Stimulant Strategy Background Paper

Create successful ePaper yourself

Delete template?

Save as template?